Last updated: May 25, 2026
Hydrochlorothiazide and Valsartan Suppliers: What Companies Provide APIs, Intermediates, and Finished Dosage Forms?
Suppliers for hydrochlorothiazide and valsartan span contract manufacturing of finished tablets, API producers, and intermediate makers. The supplier map is highly fragmented for both products, with multiple FDA-listed finished-dose manufacturers and broad global API/intermediate sourcing.
What suppliers provide hydrochlorothiazide APIs, intermediates, and finished tablets in the US?
Hydrochlorothiazide supply typically breaks into three tiers: API manufacturers, intermediate makers (key step chemicals), and finished-dose tablet packagers/CMOs that populate the US market under branded and generic labels.
Which companies supply hydrochlorothiazide API?
Hydrochlorothiazide API is produced by a wide set of manufacturers globally; many also supply through DMFs. The practical US sourcing pattern is multi-supplier to manage regulatory and commercial continuity, particularly for low-value, high-volume tablet markets.
Which companies supply hydrochlorothiazide intermediates and key starting materials?
Intermediate supply is less visible than finished-dose and API supply, but it typically includes producers of thioamide/halo-functional intermediates used in hydrochlorothiazide syntheses and subcontracted chemical transformations. Contract and regional suppliers commonly provide material under DMF cross-referencing or custom synthesis agreements.
Which firms manufacture hydrochlorothiazide tablets in the US?
US finished-dose supply is dominated by generic and labeler networks that:
- hold FDA registrations for the tablet dosage form,
- list hydrochlorothiazide on ANDAs or 505(b)(2) products where applicable,
- and use multiple outsourced API sources to preserve supply continuity.
What suppliers provide valsartan APIs, intermediates, and finished dosage forms in the US?
Valsartan has a more constrained upstream manufacturing profile than hydrochlorothiazide because of stricter process controls, higher commercial pricing than older diuretics, and recurring regulatory focus linked to impurity management.
Which companies supply valsartan APIs?
Valsartan API supply is typically concentrated among fewer large API and intermediate firms relative to low-complexity drugs. A large fraction of US market access for valsartan depends on DMF-listed API sources and regulated commercial-scale reactors with validated impurity profiles.
Which companies supply valsartan intermediates and key coupling blocks?
Valsartan production generally requires controlled synthesis of the substituted benzimidazole-like core and coupling chemistry that creates the final drug structure. Supplier networks frequently include:
- intermediate API core producers,
- specialty nitration/alkylation and coupling contractors,
- and high-purity solvent and reagent suppliers tied into process development qualification.
Which firms manufacture valsartan tablets in the US?
US finished-dose valsartan is supplied by a mix of:
- brand and authorized generic manufacturers,
- ANDA labelers and CMOs,
- and contract packagers operating under quality systems aligned with FDA expectations for ARB manufacturing impurity control.
How do hydrochlorothiazide and valsartan combination products change the supplier landscape?
Combination products (most commonly fixed-dose hydrochlorothiazide/valsartan tablets) shift supply chain constraints from only “API availability” to:
- coordinated bulk API release across both actives,
- synchronized packaging component sourcing,
- validated blending and tablet compression workflows,
- and tighter stability programs across both actives in the same dosage matrix.
Where does most integration happen: API, formulation, or packaging?
Most value chain integration happens at finished-dose manufacturing and formulation level:
- Tablet blend formulation and impurity control depend on the API lots used.
- Packaging and labeler networks often standardize on approved tablet process windows.
- Bulk API suppliers may vary across batches, but finished-dose manufacturers must qualify each incoming API lot to avoid process drift and stability failures.
Which US regulatory pathways govern supplier qualification for these drugs?
How do ANDAs affect supplier selection for hydrochlorothiazide and valsartan?
For both actives, ANDA holders typically:
- rely on one or more approved API sources tied to DMFs or cross-referenced information,
- must ensure the drug product’s sameness (bioequivalence and CMC compliance) across approved manufacturing sites,
- and maintain controlled change management for site transfers and bulk API sourcing substitutions.
How do 505(b)(2) and branded products affect upstream sourcing?
Branded and 505(b)(2) products often:
- use a defined, validated API qualification pack,
- restrict API source switching unless changes are submitted and approved,
- and maintain tighter supplier governance due to higher market liability and brand leverage.
What is the typical supplier structure for hydrochlorothiazide and valsartan products?
A usable procurement map for either active usually includes:
- API manufacturers (DMF-linked suppliers)
- Intermediate suppliers (process step contractors or integrated API groups)
- Finished-dose manufacturers (tablet makers, often using external API)
- Packagers/labelers (sometimes separate from tablet compression and coating)
- Quality and analytical vendors (stability, impurity profiling, release testing)
Which supplier risks matter most for hydrochlorothiazide and valsartan?
API quality and impurity control
Valsartan’s commercial history is more sensitive to impurity-related scrutiny, which increases supplier vetting and audit frequency. Hydrochlorothiazide generally has a more mature, lower-cost supplier base, but supply disruptions still trigger rapid requalification efforts.
Supply continuity and multi-sourcing strategy
Both actives benefit from:
- dual or multi-source API qualification,
- pre-approved alternate packaging components,
- and validated manufacturing sites for tablet production.
What supplier contracts and arrangements are most common (CMO, DMF reliance, tolling)?
For both hydrochlorothiazide and valsartan, typical arrangements include:
- CMO/tablet manufacturing: outsourcing coating, compression, and packaging under the ANDA holder’s quality system.
- DMF reliance or reference: API sourced from DMF-holding manufacturers with regulatory linkage.
- Toll manufacturing: API produced for other firms’ commercialization using shared facilities with constrained impurity specifications.
Key supplier due diligence points for procurement teams
Procurement and regulatory teams typically pressure-test suppliers on:
- DMF status and update cadence
- site audit outcomes
- impurity profiles at release and during stability
- change control discipline (process, equipment, analytical methods)
- ability to support batch traceability and rapid deviation response
- regulatory history and inspection readiness
How does supplier selection affect FDA approval and launch timelines?
Supplier changes can trigger:
- CMC supplements or prior approval requirements depending on the nature of the change
- additional stability data for requalified API lots used in new drug product batches
- potential delays if analytical methods require revalidation under the receiving site’s quality system
For combination products, the timeline risk compounds because both actives must be qualified together in the final dosage form.
What generic entry risks exist for hydrochlorothiazide, valsartan, and combo tablets based on supplier concentration?
Supplier concentration affects generic entry indirectly through:
- availability of qualified API supply in the right regulatory format,
- ability to secure stable impurity controls for valsartan,
- and manufacturing readiness for tablet production at multiple contract sites.
For procurement, the highest launch risk comes from:
- single-source API dependencies,
- difficulty qualifying alternate lots quickly enough for ANDA launch batch windows,
- and compressed timelines for CMC supplement approvals.
How strong is the supplier ecosystem compared with other diuretics and ARBs?
Compared with other ARBs, valsartan tends to have a more tightly managed impurity and process ecosystem, which can slow alternate supplier substitution. Hydrochlorothiazide typically has broader base supply, so product continuity is less sensitive to upstream concentration, though disruptions still occur.
Key Takeaways
- Hydrochlorothiazide and valsartan each rely on multi-tier supplier networks: API, intermediates, and finished-dose tablet manufacturing.
- Fixed-dose hydrochlorothiazide/valsartan products increase coordination requirements across both actives in the same tablet formulation and stability program.
- Supplier risk is driven more by API lot qualification and impurity control for valsartan than by pure availability.
- Launch timing for ANDA products depends on the ability to qualify approved API sources and execute CMC change control without triggering extended regulatory cycles.
FAQs
1) Who are the typical API suppliers for hydrochlorothiazide in the US?
Hydrochlorothiazide API supply is multi-source and commonly supplied via DMF-listed manufacturers that support ANDA and labeler networks for tablet dosage forms.
2) Which firms are most commonly involved in valsartan API supply?
Valsartan API supply is concentrated among regulated API producers with validated impurity control systems and DMF-linked regulatory documentation for US submissions.
3) How do you source APIs for fixed-dose hydrochlorothiazide/valsartan tablets?
Most manufacturers qualify approved DMF API sources for both actives, then release tablet batches using qualified bulk lots under their tablet manufacturing controls and stability programs.
4) What supplier change controls can delay ANDA launches?
API source switches, formulation process changes, and site transfers can require CMC supplements and additional stability data, which can delay launch batch approval.
5) What due diligence matters most for valsartan suppliers?
Impurity profile consistency, analytical method robustness, batch traceability, and inspection-ready quality systems are the main determinants of whether alternate suppliers can be qualified quickly.
References (APA)
- FDA. (n.d.). Drug Master Files (DMF). US Food and Drug Administration. https://www.fda.gov/
- FDA. (n.d.). ANDA (Abbreviated New Drug Application): Chemistry, Manufacturing, and Controls (CMC). US Food and Drug Administration. https://www.fda.gov/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
